Retatrutide is widely described as a triple hormone receptor agonist because it targets three signaling pathways: GLP-1 , GIP , and the glucagon receptor (GCGR)
Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
No year-long commitment is required, and no insurance is needed
Its primary actions include: Increasing attention and focus by enhancing neurotransmitter activity in prefrontal cortex regions Reducing impulsivity and hyperactivity in individuals with ADHD Suppressing appetite as a common side effect through dopaminergic and noradrenergic pathways Increasing heart rate and blood pressure due to sympathomimetic effects While semaglutide and Adderall do not interact at the pharmacokinetic level, pharmacodynamic considerations how the drugs' effects may overlap or amplifyare clinically relevant
